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http://dx.doi.org/10.10the predictive value of amyloid b(1-42) (Ab42), total tau (tau), and phosphorylated tau (ptau) in
cerebrospinal fluid (CSF) for clinical progression in patients with subjective complaints.
Methods: We recruited nondemented patients with subjective complaints (i.e., criteria for mild cog-
nitive impairment [MCI] not fulfilled) from our memory clinic. We assessed the predictive value of
CSFAb42, tau, and ptau for clinical progression using Cox proportional hazards models adjusted for
age, gender, and baseline findings on the Mini-Mental State Examination (MMSE). Clinical progres-
sion was defined as progression to MCI or AD.
Results: We included 127 patients with subjective complaints (age 606 10 years, 61 [48%] females,
MMSE 296 1). At baseline, Ab42 and tau were abnormal in 20 patients (both 16%), and ptau in 32
patients (25%). Thirteen patients (10%) progressed to MCI (n 5 11) or AD (n 5 2). Ab42 was
the strongest predictor of progression to MCI or AD with an adjusted hazard ratio (HR) of 16.0
(3.8–66.4). The adjusted HR associated with tau was 2.8 (0.9–9.2) and with ptau 2.6 (0.8–8.2).
Combinations of biomarkers had a lower predictive value than Ab42 alone.
Conclusion: LowAb42was the strongest predictor of clinical progression in patients with subjective
complaints. These results are in line with the hypothesis that the cascade of pathologic events starts
with deposition of Ab42, whereas neuronal degeneration and hyperphosphorylation of tau are more
downstream events, closer to clinical manifestation of AD.
 2013 The Alzheimer’s Association. All rights reserved.Keywords: Subjective complaints; Biomarkers; Cerebrospinal fluid; Alzheimer’s disease; Clinical progression; Predictivevalue1. Introduction
Neuropathologic changes associated with Alzheimer’s
disease (AD) are thought to precede clinical dementia by
many years [1–3]. Cerebrospinal fluid (CSF) markers of
pathologic changes could be useful to identify persons in
an early stage of AD when they have little or no cognitivethor. Tel: 131204448527; Fax: 131204448529.
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16/j.jalz.2012.08.004impairment. Recognizing AD in an early stage will become
very important with the introduction of disease-modifying
therapies.
Patients with subjective complaints form a heterogeneous
group. A considerable proportion of these patients are “wor-
ried well” and have no neurodegenerative disorder. A num-
ber of patients, however, may have early AD [4,5].
Recently, the term “preclinical AD” was introduced by two
different groups of investigators to refer to individuals who
have biomarkers consistent with AD pathology, but—likeeserved.
Fig. 1. Overview of patient selection.
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for mild cognitive impairment (MCI) or dementia [2,6]. It
was postulated these individuals would be most likely to
show clinical progression.
There is ample evidence that CSF amyloid b(1-42)
(Ab42), total tau (tau), and phosphorylated tau (ptau) predict
progression to AD dementia in patients with MCI [7–10],
and there have been a few population-based studies in which
CSF biomarkers were related to cognitive decline in healthy
subjects [11–13]. In contrast, only one study has considered
the predictive value of CSF biomarkers in patients with
subjective complaints [8]. That study showed the AD bio-
marker profile in patients with subjective complaints to be
quite common [8]. There were some indications that patients
with subjective complaints and an AD biomarker profile
were more likely to show clinical progression, but this could
not be shown conclusively, because hardly any progression
was measured during follow-up [8].
The need to recognize AD as early as possible prompted
us to assess the predictive value of CSF Ab42, tau and ptau
concentrations for clinical progression in a large group of pa-
tients with subjective complaints and a long period of fol-
low-up.2. Methods
2.1. Patients
We included patients who were considered to have sub-
jective complaints from the Alzheimer Center of the VU
University Medical Center, Amsterdam, between 2001 and
2007. At baseline, all patients underwent a standardized de-
mentia screening, including physical and neurologic exami-
nation as well as laboratory tests, electroencephalography,
(EEG) and brain magnetic resonance imaging (MRI). Cog-
nitive assessment included the Mini-Mental State Examina-
tion (MMSE) and extensive neuropsychologic testing.
Diagnoses were made in a multidisciplinary meeting, with-
out knowledge of CSF results. Patients were labeled as hav-
ing subjective complaints when they presented with
cognitive complaints, but cognitive and laboratory investiga-
tions were normal and criteria for MCI, dementia, or any
other neurologic or psychiatric disorders known to cause
cognitive complaints were not met (i.e., cognitively normal
elderly). Petersen’s criteria were used for MCI as were crite-
ria of the National Institute for Neurological and Communi-
cative Diseases–Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) for probable AD [14,15].
One hundred seventy-four of 446 patients with subjective
complaints were eligible for our study, because they under-
went lumbar puncture at baseline (Figure 1). Reasons for
not undergoing lumbar puncture included contraindications
(such as a coagulation disorder or use of coumarin) or refusal.
To be included in the study, patients were required to have
aminimal duration of follow-up of 2 years or to show clinical
progression; 33 patients did not fulfill this inclusion criterion.Five patients were not included, because they progressed to
a form of dementia other than AD. Finally, 8 patients were
excluded, because they received a different diagnosis within
6 months of baseline, suggesting a change of opinion on
baseline diagnosis, rather than progression of disease.
Thus, 128 patients were included in the analyses. Baseline
characteristics did not differ between patients included in
the analyses and those not included (data not shown).
Follow-up took place by routine visits to our memory
clinic in which patient history, cognitive tests, and a general
physical and neurologic examination were repeated. CSF re-
sults were not taken into account when follow-up diagnosis
was established. Patients who did not undergo routine
follow-up for at least 2 years after baseline were contacted
by telephone and their cognitive status was evaluated by
a standardized interview that included questions concerning
all cognitive domains, physical complaints, and medical his-
tory, complemented by the Telephone Interview for Cogni-
tive Status (TICS) [16,17]. When the telephone interview
gave rise to a suspicion of potential clinical progression,
patients were invited for a more thorough investigation at
the outpatient clinic. The primary outcome measure was
clinical progression, defined as progression to MCI or AD.
The medical ethics committee of the VUUniversityMed-
ical Center approved the study. All patients provided written
informed consent.
2.2. CSF analysis
CSFsampleswereobtainedby lumbarpuncturebetween the
L3/L4 or L4/L5 intervertebral space by a 25-gauge needle and
collected in polypropylene tubes. CSFwas centrifuged at 1800
! g for 10minutes at 4C. Part of the CSFwas used for routine
analysis, including leukocyte count, erythrocyte count, glucose
concentration, and total protein.The remainingCSFwas imme-
diately frozen at 220C until further analysis (within 2
months). CSF analysis took place at the neurology laboratory
of the VU University Medical Center, Amsterdam. Ab42,
tau, and ptau were measured using sandwich enzyme-linked
immunoassays (ELISAs; Innotest beta-amyloid1-42, Innotest
hTAU-Ag, and Innotest PhosphoTAU-181p; Innogenetics, Bel-
gium), as described elsewhere [18]. The performance of these
Table 1
Baseline characteristics by follow-up diagnosis
Subjective
complaints
(n 5 115)
Clinical
progression
(n 5 13)
Gender, female 59 (51%) 3 (23%)
Age, years 59 (10) 67 (7)y
Follow-up duration, years 3.9 (1.6) 3.2 (2.0)
MMSE (total n 5 125) 28.7 (1.3) 28.0 (1.7)
APOE ε4 positive (total n 5 120) 35 (33%) 7 (54%)
Ab42 844 (283–1274) 542 (232–1132)z
Below cut-off: 550 ng/L 12 (10%) 8 (62%)z
tau 239 (79–1134) 337 (169–993)*
Above cut-off: 375 ng/L 14 (12%) 6 (46%)z
ptau 42 (18–121) 53 (34–123)*
Above cut-off: 52 ng/L 25 (22%) 7 (54%)*
AD biomarker profile
Ab42 1 tau/ptau, n 5 (4%) 5 (39%)z
Formula of Mulder [18] 13 (11%) 7 (54%)z
Formula of Hulstaert [19] 12 (10%) 6 (46%)z
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surplus CSF (high and low biomarker values). Interassay coef-
ficients of variation (CVs) were 11.3% (4.9%) for Ab42, 9.3%
(1.5%) for tau, and 9.4% (2.5%) for ptau [18].
There is no international consensus defining what consti-
tutes an AD biomarker profile. Therefore, we evaluated each
biomarker individually and in several combinations. For in-
dividual markers we used our own previously published ref-
erence values. The following values were considered
indicative of AD pathology: ,550 ng/L for Ab42; .375
ng/L for tau; and .52 ng/L for ptau [18]. We also used the
following combinations to construct an AD biomarker pro-
file: (1) low Ab42 concentration combined with high tau
and/or ptau concentration; (2) a regression formula for an
AD biomarker profile based on data from our own laboratory
[(373 1 0.82 ! tau)/Ab42 1] [18]; and (3) a previously
published regression formula for an AD biomarker profile
[Ab42/(240 1 1.18! tau) 1] [19].NOTE. Values are presented as mean (SD), median (range) or number
(%). Analyses were performed using t-test, Mann–Whitney U-test or chi-
square test.
*P , .05.
yP , .01.
zP , .001.2.3. Statistical analysis
Data were analyzed using SPSS (version 18.0) for Macin-
tosh. Baseline characteristics were compared using t-test,
chi-square test, or Mann–Whitney U-test, as appropriate.
Cox proportional hazards models were used to assess the
predictive value of CSF biomarkers for clinical progression.
Each biomarker and all previously mentioned combinations
were evaluated as independent variables in separate analy-
ses: the first model without adjustment; the second model
adjusted for gender and age; the third model adjusted for
gender, age, and baseline MMSE; and the fourth model ad-
justed for gender, age, baseline MMSE, and dichotomized
apolipoprotein E (APOE) ε4 status. The third model in-
cluded 124 patients, because baseline MMSE data were
missing for 3 patients and the fourth included 118 patients,
because APOE status was missing for 6 additional patients.
Results are presented as hazard ratio (HR) with 95% confi-
dence interval (CI). Kaplan–Meier curves were plotted for
clinical progression with separate lines for normal and ab-
normal biomarker values. Differences between the curves
of both groups were assessed using log-rank tests.3. Results
One hundred twenty-eight patients were included in this
study (age 60 6 10 years, 61 [48%] females, MMSE 29 6
1). Mean follow-up duration was 4 6 2 years. At baseline,
Ab42 was abnormal in 20 patients (16%), tau was abnormal
in 20—partly overlapping—patients (16%), and ptau was
abnormal in 32 patients (25%). An AD biomarker profile,
defined as decreased Ab42 combined with increased tau
and/or ptau, occurred in 10 patients (8%).
Thirteen patients (10%) progressed to MCI (n 5 11) or
AD (n 5 2). Progressors were older at baseline (Table 1).
There was a trend toward a gender difference between the
groups with a predominance of men among the progressors.Baseline MMSE was 28.76 1.3 in patients with stable sub-
jective complaints and 28.06 1.7 in progressors. Concentra-
tions of CSF Ab42 were lower (P 5 .001) and tau and ptau
concentrations were higher in the progressors (P , .05).
All biomarkers were between two and five times more fre-
quently outside the reference range in the progressors (P
, .001 for Ab42 and tau, P , .05 for ptau).
Of the individual biomarkers, Ab42 was the best predic-
tor of clinical progression. The unadjusted HR of Ab42 was
11.6 (3.5–38.7) (Table 2 and Figure 2). Adjustment for age,
gender, baseline MMSE, and APOE status increased the HR
of Ab42 to 16.0 (3.8–66.4). Tau and ptau clearly had less
strong predictive values. Tau had an unadjusted HR of 4.0
(1.3–11.9), which decreased to 2.8 (0.9–9.2). The unadjusted
HR of 3.2 (1.1–9.5) of ptau decreased to 2.6 (0.8–8.2).
In addition to evaluating individual biomarkers, we also
studied several combinations that could represent an AD
biomarker profile. Although all of these combinations pre-
dicted clinical progression, Ab42 alone remained the stron-
gest predictor (see Table 2). The combination of low Ab42
with high tau and/or ptau resulted in an unadjusted HR of
9.0 (2.8–28.6). The first regression formula based on our
own data resulted in an unadjusted HR of 5.7 (1.9–17.1)
and the second regression formula based on previously pub-
lished research resulted in an unadjusted HR of 4.7 (1.6–
14.1). Adjustment for age, gender, baseline MMSE, and
APOE status did not change any of the results.
4. Discussion
We found low CSF Ab42 concentration to be a very
strong predictor of clinical progression in patients with
Table 2
Cox proportional hazard models for clinical progression (MCI/AD)
Model 1 Model 2 Model 3 (n 5 125) Model 4 (n5 118)
Ab42 11.6 (3.5–38.7)z 13.4 (3.6–49.7)z 15.1 (3.8–59.6)z 16.0 (3.8–66.4)z
tau 4.0 (1.3–11.9)* 3.0 (0.9–9.6) 3.0 (0.9–9.7) 2.8 (0.9–9.2)
ptau 3.2 (1.1–9.5)* 2.5 (0.8–7.8) 2.7 (0.9–8.3) 2.6 (0.8–8.2)
Ab42 1 tau/ptau 9.0 (2.8–28.6)z 6.5 (1.8–23.7)y 6.8 (1.8–25.9)y 7.0 (1.6–30.0)y
Formula of Mulder [18] 5.7 (1.9–17.1)y 6.2 (1.6–23.9)y 6.9 (1.7–27.6)y 7.1 (1.6–31.0)y
Formula of Hulstaert [19] 4.7 (1.6–14.1)y 4.2 (1.0–17.5)* 5.0 (1.1–23.2)* 4.1 (1.0–16.5)*
NOTE. Data presented as hazard ratio (95% CI). Model 1: Biomarker. Model 2: Biomarker1 age1 gender. Model 3: Biomarker1 age1 gender1MMSE.
Model 4: Biomarker 1 age 1 gender 1 MMSE 1 APOE status.
*P , .05.
yP , .01.
zP , .001.
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risk factors for AD. An AD biomarker profile can also pre-
dict clinical progression in patients with subjective com-
plaints, but less well than Ab42 alone. We were able to
show this in a relatively large group of patients who under-
went standardized clinical follow-up with a mean duration
of nearly 4 years.
Our findings are in line with the amyloid cascade hypoth-
esis. This hypothesis states that neuropathology of AD starts
with aggregation of amyloid, followed by hyperphosphoryla-
tion and accumulation of tau and, eventually, neuronal loss
[20,21]. This hypothesis was recently incorporated in
a dynamic biomarker view, which proposed that biomarkers
have a temporal ordering that reflects the process of
advancing AD neuropathology [22]. According to this dy-
namic biomarker view, CSF Ab42 becomes abnormal in
a very early stage when a patient is still cognitively normal.
CSF tau increases at a later stage, when the disease has pro-
gressed further [22]. Our findings provide supporting evi-
dence for this dynamic biomarker view, especially when
combined with the knowledge derived from previous MCI
studies. In MCI, CSF tau or ptau concentrations have consis-
tently been found to be better predictors of progression to AD
dementia than Ab42 [23–26]. Furthermore, combinations of
biomarkers have been shown to perform even better
[7,23,27,28]. These differences between findings in patients
with subjective complaints and MCI suggest that an AD
biomarker profile does not develop at once. Ab42 has
probably started to aggregate into oligomers and fibrils in
the subjective complaints stage of AD, whereas tangle
burden and neurodegeneration are not always sufficient to
cause elevated CSF (p)tau. When patients reach the clinical
MCI stage, more extensive neuronal loss has occurred,
resulting in abnormal CSF tau and ptau concentrations and,
consequently, a full-fledged AD biomarker profile. Temporal
organization of these events explains why the best diagnostic
biomarker for AD in CSF (an AD profile) could be different
from the best prognostic biomarker in the earliest stages of
the disease (Ab42).
In our study, a number of patients did not show clinical
progression in spite of elevated tau or ptau values. With the
previously mentioned dynamic biomarker view in mind,this may imply that elevated (p)tau has less clinical meaning
when the earlier event of low Ab42 is absent.
Contrary to our expectations the predictive values of the
three CSFAD profiles we used were very similar. Although
interassay variation was previously shown to be large when
individual concentrations of Ab42, tau, and ptau were as-
sessed [29], our results indicate that an AD profile, such as
the one defined by Hulstaert et al, has sufficient external val-
idity to predict clinical progression in patients with subjec-
tive complaints in a different cohort and laboratory than
the one in which it was developed.
The prevalence of anADbiomarker profile in a previously
published population-based sample without cognitive com-
plaints was 12% [13]. We found a prevalence of 8% when
using a similar definition of decreased Ab42 and increased
tau or ptau. The prevalence of low Ab42 alone in our study
was 16%, which seems comparable to the 20%–30% of
healthy patients with increased Pittsburgh compound B
(PiB) binding in PiB/positron emission tomography (PET)
studies [30–33]. The small difference can perhaps be
explained by the fact the earlier studies evaluated
participants older than those in our study [30–33]. The
only other study that included patients with subjective
complaints as a separate group indicated a much higher
prevalence of an AD biomarker profile. The prevalence
was 52% when using the formula of Hulstaert et al [19],
which we also used as one of our combination markers
[8]. This could have been due to analytical and preanalytical
differences between the two laboratories, resulting in differ-
ent absolute biomarker values and thereby in a different
prevalence of the AD profile. However, in one previous
study, 33 CSF samples were analyzed at both sites and the
results were very similar (e.g., Ab42 values were 593 6
294 ng/L in Amsterdam and 5586 246 ng/L in Gothenburg
[P5 .60]). Alternatively, the difference in the prevalence of
AD biomarker profile in the two cohorts may be due to dif-
ferences in age and genetic background of the study samples,
as the subjects in the former study were older and had
a higher prevalence of the APOE ε4 genotype. Subtle differ-
ences between inclusion criteria and definitions of categories
used may also partly explain the differences between the
two studies.
Fig. 2. Kaplan–Meier curves for Ab42, tau, ptau and an AD biomarker profile. Kaplan–Meier curves for clinical progression with separate lines for CSF bio-
marker values within the reference range (uninterrupted lines) and values outside the reference range (dotted lines). Vertical lines represent censored data. The
numbers entering the intervals of 0, 2, and 4 years are depicted below each figure. An AD biomarker profile was defined as: (3731 0.82! tau)/Ab421 [18].
Log rank tests were performed to assess the difference between both lines in each plot. All differences were significant (P, .001 for Ab42 and the AD profile, P
, .01 for tau, and P , .05 for ptau).
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CSF biomarkers in patients without cognitive impairment
[11,13,34,35], or groups of “healthy” subjects that may not
have excluded MCI patients [12]. Consistent with our re-
sults, CSFAb42 was found to be the best predictor of cogni-
tive decline and dementia in several population-based
samples [12,34,35]. Also, an AD profile predicted
cognitive decline [11,13,35]. Recent PiB/PET studies
indicated similar results, showing increased PiB binding to
be predictive of clinical progression in healthy oldersubjects [30,36,37]. One of these imaging studies also
included hippocampal atrophy and fludeoxyglucose/PET as
markers for neurodegeneration [37]. Similar to our results
both a positive PiB/PET scan and a combination of amyloid
and neurodegenerativemarkers were associated with clinical
progression [37]. In contrast to our findings, a study of 90
community-dwelling elderly with a clinical dementia rating
scale (CDR) of 0, where CSF Ab42 alone was used, did not
predict clinical progression, whereas an combination of CSF
biomarkers did [11]. Amore recent CSF study from the same
A.C. van Harten et al. / Alzheimer’s & Dementia 9 (2013) 481–487486investigators assessed 213 subjects with a CDR score of 0,
who were, on average, 10 years younger than those in the
earlier study [35]. On this occasion, the results were more
similar to ours: Ab42 performed best in the unadjusted
models and just as well as the AD profiles in the adjusted
models [35]. A likely explanation for the different results
is that, because the participants were older, the earlier CSF
study had patients with more advanced AD pathology.
This is supported by a much higher progression rate in those
studies, both in comparison to our current data and the more
recent CSF study [11,35]. Only one previous study assessed
the predictive value of CSF biomarkers in a group of patients
with subjective complaints [8]. In that study an AD bio-
marker profile was highly prevalent, but did not predict cog-
nitive decline. The most likely explanation seems to be that
a mean follow-up duration of 2.4 years was too short to de-
tect any relevant progression. In general, it seems that our
patients with subjective complaints were similar to
”healthy” subjects of the same age taken from the general
population, both in terms of amount of AD pathology pres-
ent and predictive value of CSF biomarkers.
A major strength of the current study is that we utilized
a relatively large patient cohort, with all participants undergo-
ing an extensive and standardized clinical work-up. Also, pa-
tients were followed for a substantial amount of time. Among
the possible limitations of our study is the outcome measure
used. We used clinical diagnoses as outcome measures with-
out pathologic confirmation. It is, however, unlikely that pro-
gressors had a different underlying pathology than AD,
because the sensitivity of NINCDS-ADRDA criteria for AD
is good and most of the MCI patients had amnestic MCI,
which makes an underlying AD pathology likely [38–41].
The term “preclinical AD” seems to accurately describe
patients with subjective complaints and CSF biomarkers
consistent with AD, especially those with low Ab42 [2].
Our data suggest that the neuropathologic disease stage of
patients with subjective complaints is best compared to
that of individuals with the same CSF profile, without any
complaints or impairment. Our patients, however, are in
a unique position, because they do seek medical care, which
makes them available for disease-modifying therapies at
a time when the AD brain may still be salvageable [42]. In
the future this could be of utmost importance with regard
to the way patients are selected for clinical trials. Still, in
our opinion, it is too early for diagnostic use of the term pre-
clinical AD. Future studies with larger samples and longer
follow-up will be needed to prove whether all individuals
with low CSF Ab42 will eventually develop AD dementia
or if clinical progression can still be prevented by (unknown)
protective factors.
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